ResMed Stock Forecast, Price & News

ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed or view top-rated stocks.

How has ResMed's stock been impacted by COVID-19 (Coronavirus)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RMD stock has increased by 65.9% and is now trading at $254.85.
View which stocks have been most impacted by COVID-19.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, January 27th 2022.
View our earnings forecast for ResMed.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its earnings results on Thursday, October, 28th. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.35 by $0.16. The medical equipment provider had revenue of $904 million for the quarter, compared to analyst estimates of $858.20 million. ResMed had a net margin of 14.92% and a trailing twelve-month return on equity of 28.46%. ResMed's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.27 EPS.
View ResMed's earnings history.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, October 28th. Investors of record on Thursday, November 11th will be given a dividend of $0.42 per share on Thursday, December 16th. This represents a $1.68 annualized dividend and a yield of 0.66%. The ex-dividend date is Tuesday, November 9th.
View ResMed's dividend history.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.65%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 49.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 24.71% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

10 brokerages have issued twelve-month target prices for ResMed's shares. Their forecasts range from $221.00 to $270.00. On average, they anticipate ResMed's stock price to reach $244.43 in the next twelve months. This suggests that the stock has a possible downside of 4.1%.
View analysts' price targets for ResMed or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:

• Mick Farrell, Chief Executive Officer & Director
• Rob Douglas, President & Chief Operating Officer
• Brett A. Sandercock, Chief Financial Officer
• Carlos M. Nunez, Chief Medical Officer
• Bobby Ghoshal, Chief Technology Officer & President-SaaS Business

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ResMed's key competitors?

Some companies that are related to ResMed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), DexCom (DXCM), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Masimo (MASI) and Abiomed (ABMD).
View all of RMD's competitors.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.71%), WCM Investment Management LLC (6.24%), Capital World Investors (2.52%), Geode Capital Management LLC (2.02%), Baillie Gifford & Co. (1.96%) and Invesco Ltd. (1.22%). Company insiders that own ResMed stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Morgan Stanley, Victory Capital Management Inc., Eagle Asset Management Inc., Bank of New York Mellon Corp, Martingale Asset Management L P, Schroder Investment Management Group, and NFJ Investment Group LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Geode Capital Management LLC, Goldman Sachs Group Inc., Martin Currie Ltd., Los Angeles Capital Management LLC, Barclays PLC, and Capstone Investment Advisors LLC.
View insider buying and selling activity for ResMed or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $254.85.

How much money does ResMed make?

ResMed has a market capitalization of $37.14 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $3.41 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,970 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

ResMed is headquartered at 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000, via email at [email protected], or via fax at 858-836-5501.